Expression of Kinase-defective Mutants of c-Src in Human Metastatic Colon Cancer Cells Decreases Bcl-xL and Increases Oxaliplatin- and Fas-induced Apoptosis
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Tumor resistance to current drugs prevents curative treatment of human colon cancer. A pressing need for effective, tumor-specific chemotherapies exists. The non-receptor-tyrosine kinase c-Src is overexpressed in >70% of human colon cancers and represents a tractable drug target. KM12L4A human metastatic colon cancer cells were stably transfected with two distinct kinase-defective mutants of c-src. Their response to oxaliplatin, to SN38, the active metabolite of irinotecan (drugs active in colon cancer), and to activation of the death receptor Fas was compared with vector control cells in terms of cell cycle arrest and apoptosis. Both kinase-defective forms of c-Src co-sensitized cells to apoptosis induced by oxaliplatin and Fas activation but not by SN38. Cells harboring kinase-defective forms of c-Src carrying function blocking point mutations in SH3 or SH2 domains were similarly sensitive to oxaliplatin, suggesting that reduction in kinase activity and not a Src SH2-SH3 scaffold function was responsible for the observed altered sensitivity. Oxaliplatin-induced apoptosis, potentiated by kinase-defective c-Src mutants, was dependent on activation of caspase 8 and associated with Bid cleavage. Each of the stable cell lines in which kinase-defective mutants of c-Src were expressed had reduced levels of Bcl-x(L.) However, inhibition of c-Src kinase activity by PP2 in vector control cells did not alter the oxaliplatin response over 72 h nor did it reduce Bcl-x(L) levels. The data suggest that longer term suppression of Src kinase activity may be required to lower Bcl-x(L) levels and sensitize colon cancer cells to oxaliplatin-induced apoptosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, evidence from preclinical studies in sarcoma and ovarian cancer cell lines suggests that activation of Src reduces sensitivity to various chemotherapeutic drugs, including platinum agents, and that this resistance can be reversed by pharmacological inhibition [19, 20][21–23][24].”
From Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src (2016) · cites this paper as [21]
In the citing paper
“Moreover, expression of a dominant negative, kinase-defective Src mutant resulted in increased sensitivity to oxaliplatin-mediated apoptosis in KM12L4 human colon tumor cells in vitro [21].”
From Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src (2016) · cites this paper as [21]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Scudiero, D. A., Shoemaker, R. H., Paull, K. D., Monks, A. P., Tierney, S., Nofziger, T. H., Currens, M. J., Seniff, D. A., & Boyd, M. R. (1988) · PubMed · Cited by 2,737
Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor
Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., & Connelly, P. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.695 · Cited by 1,939
Src in cancer: deregulation and consequences for cell behaviour
Frame, M. C. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00040-9 · Cited by 683
Self-citationStat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation
Turkson, J., Bowman, T., Garcia, R., Caldenhoven, E., De Groot, R. P., & Jove, R. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.5.2545 · Cited by 651
Pelengaris, S., Khan, M., & Evan, G. I. (2002) · Cell · doi:10.1016/s0092-8674(02)00738-9 · Cited by 626
Stat3 Activation Is Required for Cellular Transformation by v- src
Bromberg, J. F., Horvath, C. M., Besser, D., Lathem, W. W., & Darnell, J. E. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.5.2553 · Cited by 614
Martin, G. S. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35073094 · Cited by 599
Activating SRC mutation in a subset of advanced human colon cancers
Irby, R. B., Mao, W., Coppola, D., Kang, J., Loubeau, J. M., Trudeau, W., Karl, R., Fujita, D. J., Jove, R., & Yeatman, T. J. (1999) · Nature Genetics · doi:10.1038/5971 · Cited by 489
Flow Cytometry: A Practical Approach
Ormerod, M. G. (1994) · Cited by 452
Activation of BTK by a Phosphorylation Mechanism Initiated by SRC Family Kinases
Rawlings, D. J., Scharenberg, A. M., Park, H., Wahl, M. I., Lin, S., Kato, R. M., Fluckiger, A.-C., Witte, O. N., & Kinet, J.-P. (1996) · Science · doi:10.1126/science.271.5250.822 · Cited by 445
Selected glimpses into the activation and function of Src kinase
Bjorge, J. D., Jakymiw, A., & Fujita, D. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203923 · Cited by 412
Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer.
Talamonti, M. S., Roh, M. S., Curley, S. A., & Gallick, G. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116200 · Cited by 399
Drug-target interactions: only the first step in the commitment to a programmed cell death?
Dive, C., & Hickman, J. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.269 · Cited by 398
Self-citationYoung, M. A., Gonfloni, S., Superti-Furga, G., Roux, B., & Kuriyan, J. (2001) · Cell · doi:10.1016/s0092-8674(01)00301-4 · Cited by 386
Morikawa, K., Walker, S. M., Jessup, J. M., & Fidler, I. J. (1988) · PubMed · Cited by 364
Activation and Association of Stat3 with Src in v-Src-Transformed Cell Lines
Cao, X., Tay, A., Guy, G. R., & Tan, Y. H. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.4.1595 · Cited by 359
Fas Ligand-independent, FADD-mediated Activation of the Fas Death Pathway by Anticancer Drugs
Micheau, O., Solary, E., Hammann, A., & Dimanche-Boitrel, M.-T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.7987 · Cited by 320
v-SRC'S hold over actin and cell adhesions
Frame, M. C., Fincham, V. J., Carragher, N. O., & Wyke, J. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm779 · Cited by 305
Self-citationApoptosis and cancer chemotherapy
Makin, G., & Dive, C. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02124-9 · Cited by 297
Self-citationExpression of Fas ligand in liver metastases of human colonic adenocarcinomas
Shiraki, K., Tsuji, N., Shioda, T., Isselbacher, K. J., & Takahashi, H. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6420 · Cited by 252
Karni, R., Jove, R., & Levitzki, A. (1999) · Oncogene · doi:10.1038/sj.onc.1202835 · Cited by 242
Rosen, K., Coll, M. L., Li, A., & Filmus, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106424200 · Cited by 202
Mao, W., Irby, R., Coppola, D., Fu, L., Wloch, M., Turner, J., Yu, H., Garcia, R., Jove, R., & Yeatman, T. J. (1997) · Oncogene · doi:10.1038/sj.onc.1201496 · Cited by 200
Birner, P., Gatterbauer, B., Oberhuber, G., Schindl, M., Rössler, K., Prodinger, A., Budka, H., & Hainfellner, J. A. (2001) · Cancer · doi:10.1002/1097-0142(20010701)92:1<165::aid-cncr1305>3.0.co;2-f · Cited by 195
Mitochondrial membrane permeabilisation by Bax/Bak
Esposti, M. D., & Dive, C. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00617-x · Cited by 194
Self-citationDuxbury, M. S., Ito, H., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1183-3 · Cited by 192
Falcone, A., Masi, G., Allegrini, G., Danesi, R., Pfanner, E., Brunetti, I. M., Di Paolo, A., Cupini, S., Del Tacca, M., & Conte, P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.075 · Cited by 156
Bruton's Tyrosine Kinase as an Inhibitor of the Fas/CD95 Death-inducing Signaling Complex
Vassilev, A. O., Özer, Z., Navara, C. S., Mahajan, S., & Uckun, F. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.3.1646 · Cited by 137
Suzuki, T., Yokozaki, H., Kuniyasu, H., Hayashi, K., Naka, K., Ono, S., Ishikawa, T., Tahara, E., & Yasui, W. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001215)88:6<992::aid-ijc24>3.0.co;2-9 · Cited by 121
Avizienyte, E., Fincham, V. J., Brunton, V. G., & Frame, M. C. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-12-0879 · Cited by 114
Self-citationRegulation of Btk by Src Family Tyrosine Kinases
Afar, D. E. H., Park, H., Howell, B. W., Rawlings, D. J., Cooper, J., & Witte, O. N. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.7.3465 · Cited by 104
Tillman, D. M., Peták, I., & Houghton, J. A. (1999) · PubMed · Cited by 98
Belka, C., Marini, P., Lepple-Wienhues, A., Budach, W., Jekle, A., Łoś, M., Lang, F. J. W., Schulze‐Osthoff, K., Gulbins, E., & BAMBERG, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202878 · Cited by 92
Hakak, Y., Hsu, Y. S., & Martin, G. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203655 · Cited by 83
Regulation of both apoptosis and cell survival by the v-Src oncoprotein
Johnson, D., Agochiya, M., Samejima, K., Earnshaw, W. C., Frame, M. C., & Wyke, J. A. (2000) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400700 · Cited by 82
Self-citationJones, R. J., Avizienyte, E., Wyke, A. W., Owens, D. W., Brunton, V. G., & Frame, M. C. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600594 · Cited by 80
Self-citationTranslating basic cancer research into new cancer therapeutics
Workman, P., & Kaye, S. B. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02319-5 · Cited by 74
Self-citationLoza‐Coll, M., Rosen, K. V., Ladeda, V., & Filmus, J. (2002) · Oncogene · doi:10.1038/sj.onc.1205388 · Cited by 73
Recchia, I., Rucci, N., Funari, A., Migliaccio, S., Taranta, A., Longo, M., Kneissel, M., Šuša, M., Fabbro, D., & Teti, A. M. (2003) · Bone · doi:10.1016/j.bone.2003.06.004 · Cited by 72
Micheau, O., Hammann, A., Solary, É., & Dimanche‐Boitrel, M. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0391 · Cited by 64
Chen, G., Shu, J., & Stacey, D. W. (1997) · Oncogene · doi:10.1038/sj.onc.1201347 · Cited by 59
Tseng, Y., Hong, R., Tao, M., & Chang, F. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990301)80:5<704::aid-ijc13>3.0.co;2-z · Cited by 57
Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives
Wils, J. A., O'Dwyer, P. J., & Labianca, R. (2001) · Annals of Oncology · doi:10.1023/a:1008357725209 · Cited by 57
v-Src Generates a p53-Independent Apoptotic Signal
Webb, B. L., Jimenez, E., & Martin, G. S. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.24.9271-9280.2000 · Cited by 52
The tyrosine kinase Lck is involved in regulation of mitochondrial apoptosis pathways
Belka, C., Gruber, C., Jendrossek, V., Wesselborg, S., & Budach, W. (2003) · Oncogene · doi:10.1038/sj.onc.1206103 · Cited by 33
Boudný, V., & Nakano, S. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600080 · Cited by 27
Intestinal cell growth control: Role of Src tyrosine kinases
Cartwright, C. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70443-3 · Cited by 13
Research works printed but not linked: 7
- Frame, 2002, Biochim. Biophys. Acta, 1602, 114
- Cam, 2001, Cancer, 92, 61, 10.1002/1097-0142(20010701)92:1<61::aid-cncr1292>3.0.co;2-d · DOI · Paper page
- Scudiero, 1988, Cancer Res., 48, 4827
- Kinoshita, 2000, Int. J. Cancer, 88, 986, 10.1002/1097-0215(20001215)88:6<986::aid-ijc23>3.0.co;2-b · DOI · Paper page
- Tillman, 1999, Clin. Cancer Res., 5, 425
- Morikawa, 1988, Cancer Res., 48, 1943
- Masumoto, 1999, Int. J. Cancer, 80, 731, 10.1002/(sici)1097-0215(19990301)80:5<731::aid-ijc17>3.0.co;2-h · doi:10.1002/(sici)1097-0215(19990301)80:5<731::aid-ijc17>3.0.co;2-h
Cited by
Targeting Src in breast cancer
Finn, R. S. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn291 · Cited by 248
“Src inhibition has also been shown to augment the therapeutic effects of cytotoxic chemotherapy drugs in vitro [70, 71].”
BackgroundShakibaei, M., Mobasheri, A., Lueders, C., Busch, F., Shayan, P., & Goel, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057218 · Cited by 226
“Indeed, it has been reported that suppression of Src signaling sensitizes tumor cells to chemotherapies [56,57].”
BackgroundSrc kinase phosphorylates Caspase‐8 on Tyr380: a novel mechanism of apoptosis suppression
Cursi, S., Rufini, A., Stagni, V., Condò, I., Matafora, V., Bachi, A., Bonifazi, A. P., Coppola, L., Superti‐Furga, G., Testi, R., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601085 · Cited by 205
“Interestingly, inhibition of Src sensitizes human colon cancer cell lines to Fas-induced apoptosis (Griffiths et al, 2004).”
BackgroundKopetz, S., Lesslie, D. P., Dallas, N. A., Park, S. I., Johnson, M., Parikh, N. U., Kim, M. P., Abbruzzese, J. L., Ellis, L. M., Chandra, J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2246 · Cited by 160
“Our data imply that the combination of dasatinib and oxaliplatin will not affect all colon tumor cells, as also shown by others (15).”
Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells
Nautiyal, J., Kanwar, S. S., Yu, Y., & Majumdar, A. P. N. (2011) · Journal of Molecular Signaling · doi:10.1186/1750-2187-6-7 · Cited by 146
“Pre-clinical evidence indicates that inhibition of Src renders the cancer cells susceptible to chemotherapies [44-46].”
Background
Metadata
- Authors
- Griffiths, G. J., Koh, M. Y., Brunton, V. G., Cawthorne, C., Reeves, N. A., Greaves, M., Tilby, M. J., Pearson, D. G., Ottley, C. J., Workman, P., Frame, M. C., & Dive, C.
- Affiliations
- Cancer Research UK (GB)
- Newcastle University (GB)
- Durham University (GB)
- Institute of Cancer Research (GB)
- Cancer Research UK Scotland Institute (GB)
- Corresponding author
- Dive, Caroline
- ORCID
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-10
- Volume
- 279
- Issue
- 44
- Pages
- 46113-46121
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2136103100
- Cited by
- 60
- References
- 48
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 2 · 2019: 1 · 2017: 2 · 2016: 2 · 2015: 3 · 2014: 3 · 2013: 4
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5832 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Durham Research Online (Durham University) (acceptedVersion)
- Durham Research Online (Durham University) (submittedVersion, cc-by)
- Research Explorer (The University of Manchester) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- Src kinase, colon cancer, metastatic colon cancer, oxaliplatin, Fas-mediated apoptosis, Bcl-xL, SN-38, irinotecan, caspase-8, Bid cleavage, apoptosis sensitization, SH2 domain, SH3 domain, PP2, non-receptor tyrosine kinase, drug resistance
- MeSH terms
- Oxaliplatin, CSK Tyrosine-Protein Kinase, Colonic Neoplasms, Humans, Mutation, Neoplasm Metastasis, Organoplatinum Compounds, Protein-Tyrosine Kinases, Pyrimidines, Apoptosis, fas Receptor, src-Family Kinases, Proto-Oncogene Proteins c-bcl-2, Caspases, Cell Line, Tumor, bcl-X Protein, Caspase 8
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.